Literature DB >> 10753212

Promotion of intestinal carcinogenesis by Streptococcus bovis.

S Ellmerich1, M Schöller, B Duranton, F Gossé, M Galluser, J P Klein, F Raul.   

Abstract

The involvement of Streptococcus bovis, an member of the human gut flora, in colorectal neoplastic diseases is an object of controversy. The aim of this study was to determine the effects of S.bovis and of antigens extracted from the bacterial cell wall on early preneoplastic changes in the intestinal tract. Adult rats received i. p. injections of azoxymethane (15 mg/kg body weight) once per week for 2 weeks. Fifteen days (week 4) after the last injection of the carcinogen, the rats received, by gavage twice per week during 5 weeks, either S.bovis (10(10) bacteria) or wall-extracted antigens (100 microg). One week after the last gavage (week 10), we found that administration of either S.bovis or of antigens from this bacterium promoted the progression of preneoplastic lesions through the increased formation of hyperproliferative aberrant colonic crypts, enhanced the expression of proliferation markers and increased the production of IL-8 in the colonic mucosa. Our study suggests that S.bovis acts as a promoter of early preneoplastic lesions in the colon of rats. The fact that bacterial wall proteins are more potent inducers of neoplastic transformation than the intact bacteria may have important implications in colon cancer prevention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10753212     DOI: 10.1093/carcin/21.4.753

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  72 in total

Review 1.  A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects.

Authors:  Harold Tjalsma; Annemarie Boleij; Julian R Marchesi; Bas E Dutilh
Journal:  Nat Rev Microbiol       Date:  2012-06-25       Impact factor: 60.633

Review 2.  Relationship between intestinal microbiota and colorectal cancer.

Authors:  Gokhan Cipe; Ufuk Oguz Idiz; Deniz Firat; Huseyin Bektasoglu
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

3.  Microbial Metabolites as Molecular Mediators of Host-Microbe Symbiosis in Colorectal Cancer.

Authors:  N P Hyland; A Houston; J M Keane; S A Joyce; C G M Gahan
Journal:  Results Probl Cell Differ       Date:  2020

4.  Streptococcus bovis endophthalmitis: a unique presentation of colon cancer.

Authors:  Wissam Bleibel; Karl D'Silva; Ali Elhorr; Samer Bleibel; Upandra Dhanjal
Journal:  Dig Dis Sci       Date:  2007-04-19       Impact factor: 3.199

Review 5.  The microbiome and colorectal neoplasia: environmental modifiers of dysbiosis.

Authors:  N D Turner; L E Ritchie; R S Bresalier; R S Chapkin
Journal:  Curr Gastroenterol Rep       Date:  2013-09

6.  Prolonged and repetitive exposure to Porphyromonas gingivalis increases aggressiveness of oral cancer cells by promoting acquisition of cancer stem cell properties.

Authors:  Na Hee Ha; Bok Hee Woo; Da Jeong Kim; Eun Sin Ha; Jeom Il Choi; Sung Jo Kim; Bong Soo Park; Ji Hye Lee; Hae Ryoun Park
Journal:  Tumour Biol       Date:  2015-07-16

7.  Listeria monocytogenes produces a pro-invasive factor that signals via ErbB2/ErbB3 heterodimers.

Authors:  Maria José Oliveira; Tineke Lauwaet; Georges De Bruyne; Marc Mareel; Ancy Leroy
Journal:  J Cancer Res Clin Oncol       Date:  2004-10-08       Impact factor: 4.553

Review 8.  Streptococcus bovis endocarditis and colon cancer: myth or reality? A case report and literature review.

Authors:  Salvatore Galdy; Giuseppe Nastasi
Journal:  BMJ Case Rep       Date:  2012-12-05

Review 9.  Infectious agents and colorectal cancer: a review of Helicobacter pylori, Streptococcus bovis, JC virus, and human papillomavirus.

Authors:  Andrea N Burnett-Hartman; Polly A Newcomb; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

Review 10.  Bacterial oncogenesis in the colon.

Authors:  Christine Dejea; Elizabeth Wick; Cynthia L Sears
Journal:  Future Microbiol       Date:  2013-04       Impact factor: 3.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.